Roche的实验性Parkinson的药物在早期病人身上显示出希望,尽管缺少初级研究目标。 Roche's experimental Parkinson's drug showed promise in early-stage patients, despite missing primary study goals.

Roche的实验药物Pasisenezumab在一项中阶段研究中显示了早期帕金森病人的潜在好处,尽管未能实现其主要目标。 Roche's experimental drug prasinezumab showed potential benefits for early-stage Parkinson's disease patients in a mid-stage study, despite failing to meet its main goal. 该药物针对与帕金森氏蛋白质有关的蛋白质,显示出运动机能下降放缓的积极趋势,并获得良好治疗。 The drug, which targets proteins linked to Parkinson's, demonstrated positive trends in slowing motor decline and was well-tolerated. Roche将与卫生当局磋商,以确定治疗的下一步步骤。 Roche will consult with health authorities to determine next steps for the treatment.